Navigation Links
University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
Date:8/15/2012

MIAMI, Aug. 15, 2012 /PRNewswire/ -- A published University of Miami study using Rice Bran Arabinoxylan Compound (RBAC) has showed  RBAC demonstrated significant immunomodulary activity based upon the observed changes in natural killer cell cytotoxicity (NKCC) and the cytokines and growth factors. Specifically, the study showed that the short term rise in NKCC and in 9 of 12 cytokines and growth factors are evident that RBAC is a potent immunomodulator. The study was published July 28, 2012 in Functional Foods in Health and Disease (Volume 2, Issue 7), http://functionalfoodscenter.net/The_Journal_of_FFHD__Page_3.html.

RBAC may help to destroy tumor cells and viruses directly, and increase the activity of immune cells, thereby optimizing the immune system, especially NKCC, which can increase the chance and speed of host recovery. Researchers note that the immunomodulatory activity merits further study in conditions where the immune system is functionally compromised, such as otherwise healthy smokers and HIV/AIDS or cancer patients.

RBAC is a nutritional supplement produced by enzymatic hydrolysis of hemicellulose B derived from rice bran. Several in vitro studies and clinical reports have shown RBAC to possess promising immunomodulating effects, specifically with respect to natural killer cell and cytokine activity.

The concept of a true immunomodulator is an agent possessing a broad range of activity dependent upon the existing state of health and immunity in the individual host. The Miami University study investigated the immunomodulatory effect of RBAC in a healthy adult human population over 60 days by assessing changes in NKCC and cytokines and growth factors.

According to Dr. John Lewis, Ph.D. associate professor, department of psychiatry and behavioral sciences at the University of Miami, Miller School of Medicine, and corresponding research author, this study represents a first step in testing this product in healthy adults. 

"We showed that the product is safe according to protein, bilirubin, and liver function tests, and that RBAC is capable of true immunomodulation, not stimulation or suppression," said Dr. Lewis. "In other words, the immune factors that we analyzed showed bi-directional, transient responses in people who were healthy without chronic disease," Dr. Lewis added.

"Our results are valid based on the statistical analysis that we performed in the study and appear to be consistent with the findings of other investigators as well," said Dr. Lewis.

The study was sponsored by Gardena, CA-based Daiwa Health Development. RBAC product for this study was supplied by Daiwa Health Development.

Dr. Aaron H. Wolfson, M.D., professor and vice chairman of the department of radiation oncology at the University of Miami, Miller School of Medicine, co-author in the study, and a proponent of RBAC since 2002, added, "we are eagerly looking to expand the use of RBAC in patients with end stage solid tumors (cancers) in the near future in a phase one trial as a preliminary study to evaluate PeakImunne4 as a potential therapeutic agent in treating these terminal patients."

RBAC is manufactured by Daiwa Health Development, and sold commercially as PeakImmune4®, an essential, broad spectrum immune support dietary supplement providing vital antioxidant and anti-inflammatory action. RBAC is a polysaccharide dietary fiber derived from rice bran and is modified by an enzyme from Shiitake mushrooms using a patented biotechnology process.

Daiwa has become a leading research and manufacturing company, striving to create new value in the field of bioscience in the U.S. and worldwide.

For complete study information call 877.434.3633 or email Info@DHDMED.com.

 

For more Information:
Karena Dillon
Baker Dillon Group
Info@BakerDillon.com  
559.325.7191

 


'/>"/>
SOURCE Daiwa Health Development
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
2. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
3. Worlds smallest semiconductor laser created by University of Texas scientists
4. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
5. University of Utah physicists invent spintronic LED
6. University of Nottingham to play key role in European solar energy technology project
7. Western Carolina University, College of Business Appoints New Director of Entrepreneurship and Innovation
8. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
9. University of Utah chemists use nanopores to detect DNA damage
10. Stevenage Bioscience Catalyst to Welcome Cambridge University Researchers
11. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, ... , a leading digital health company, and ... of telemedicine and remote patient monitoring, announce they ... reimbursements.  DN Telehealth maximizes collaboration ... real-time, extending consultations beyond a physical clinical setting ...
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... INDIANAPOLIS, Ind. (PRWEB) , ... February 23, 2017 ... ... Commercialization Award during the 12th annual Inventors Recognition Reception at Purdue Research ... annually to a faculty member in recognition of outstanding contributions to, and success ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/6/2017)... 6, 2017 According to Acuity Market ... border authorities to continue to embrace biometric and ... 2143 Automated Border Control (ABC) eGates and 1436 ... more than 163 ports of entry across the ... achieving a combined CAGR of 37%. APC Kiosks ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
Breaking Biology News(10 mins):